Publication date: 20th July 2022
In this video module, Program Director Nadia Harbeck and Patient Advocate Renate Haidinger discuss the importance of shared decision making throughout the course of a patient’s treatment, including the communication of risk, and decisions on testing, therapies and adverse event management.
Learning objectives
After completing this activity, you will be able to:
- Discuss best practice for communicating about recurrence risk and treatment options with those diagnosed with HR+/HER2- early breast cancer
- Integrate tools and guidance on shared decision making to ensure patient preference is a high priority when choosing the management strategy
Accreditation
Expiration date: 20th July 2023
Estimated time to complete: 15 minutes
When you have completed this activity you will be asked to fill in a short evaluation survey. Your feedback helps us to give you the best learning experience.
Download the communication aid
Nadia and Renate’s conversation has been summarised into a practical communication aid, listing key considerations from both the clinician and patient point of view for shared decision making with HR+/HER2- early breast cancer patients.
Please select your preferred language to access the communication aid.
Sign up for new content alerts
Enter your email address below and we'll contact you as soon as new content is launched!
